About Index Trending news
Analyze
Top 50 Pricing

Clinical Trials

10–100 Companies
Companies

Growing

49
Funding and Acquisitions

2016 Q4

3 + 1
Curators of Clinical Trials
Finextra

Chiltern railways to trial ticket-free travel

$4,500,000 Venture capital (Series A)
FinSMEs

Circle Pharma Raises over $4.5M in Series A Funding

$16,500,000 Venture capital
FinSMEs , prnewswire

MedNet Solutions Raises $16.5m in Second Funding

Funding
Acquisition
mna , foxwilmington , yourohiovalley

Mergers & Acquisitions - PatientPoint, acquired MedCenterDisplay

$1,500,000 Seed fund
FinSMEs

Intent Solutions Raises $1.5M In Seed Funding

Finextra

Chiltern Railways to test smartphone detection payment system

Seed fund
FinSMEs

Healthcare Company Abreos Biosciences Raises Seed Funding Round

The Motley Fool

The $100 Million Platform Intrexon Investors Forgot

The Motley Fool

Why Intrexon Won't Commercialize Fuels by 2018

The Motley Fool

Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.

The Motley Fool

Intrexon Battles Thermodynamics, but Thermodynamics Always Wins

The Motley Fool

Intrexon vs. MosquitoMate: Who Has the Better Zika Tool?

$23,000,000 Venture capital (Series B)
businesswire , FinSMEs

Omicia Raises $23 Million in Series B Funding | Business Wire

The Motley Fool

Here's Why Intrexon Corporation Was All the Buzz in May

The Motley Fool

Regulatory Obstacles and Opportunities Facing Intrexon's Natural-Gas-to-Fuels Platform

The Motley Fool

Why Intrexon and Dominion Resources Are Excited About Natural Gas-to-Fuels

$1,700,000 Venture capital
prnewswire , FinSMEs

Dallas-Based Bone Solutions, Inc. Receives $1.7 million in Funding

The Motley Fool

Intrexon's Risky Revenue Machine

The Motley Fool

Intrexon Delivers Revenue Growth (Again) While Avoiding Elephant in the Room

Earnings Stock markets
The Motley Fool

Intrexon Corporation Shares Were Stung in April -- Here's Why